Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner.
We investigated the effect of protein kinase A (PKA) on passive force in skinned cardiac tissues that express different isoforms of titin, i.e., stiff (N2B) and more compliant (N2BA) titins, at different levels. We used rat ventricular (RV), bovine left ventricular (BLV), and bovine left atrial (BLA) muscles (passive force: RV > BLV > BLA, with the ratio of N2B to N2BA titin, approximately 90:10, approximately 40:60, and approximately 10:90%, respectively) and found that N2B and N2BA isoforms can both be phosphorylated by PKA. Under the relaxed condition, sarcomere length was increased and then held constant for 30 min and the peak passive force, stress-relaxation, and steady-state passive force were determined. Following PKA treatment, passive force was significantly decreased in all muscle types with the effect greatest in RV, lowest in BLA, and intermediate in BLV. Fitting the stress-relaxation data to the sum of three exponential decay functions revealed that PKA blunts the magnitude of stress-relaxation and accelerates its time constants. To investigate whether or not PKA-induced decreases in passive force result from possible alteration of titin-thin filament interaction (e.g., via troponin I phosphorylation), we conducted the same experiments using RV preparations that had been treated with gelsolin to extract thin filaments. PKA decreased passive force in gelsolin-treated RV preparations with a magnitude similar to that observed in control preparations. PKA was also found to decrease restoring force in skinned ventricular myocytes of the rat that had been shortened to below the slack length. Finally, we investigated the effect of the beta-adrenergic receptor agonist isoprenaline on diastolic force in intact rat ventricular trabeculae. We found that isoprenaline phosphorylated titin and that it reduced diastolic force to a degree similar to that found in skinned RV preparations. Taken together, these results suggest that during beta-adrenergic stimulation, PKA increases ventricular compliance in a titin isoform-dependent manner.
Fukuda
Norio
N
Department of Veterinary and Comparative Anatomy, Pharmacology and Physiology, Washington State University, Pullman, WA 99164, USA.
Wu
Yiming
Y
Nair
Preetha
P
Granzier
Henk L
HL
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D002417:Cattle; D064211:Connectin; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D004548:Elasticity; D018260:Gelsolin / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009124:Muscle Proteins / Q000378:metabolism*; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D010210:Papillary Muscles / Q000187:drug effects / Q000502:physiology*; D010766:Phosphorylation / Q000187:drug effects; D020033:Protein Isoforms / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism*; D051381:Rats
D000318:Adrenergic beta-Agonists; D064211:Connectin; D018260:Gelsolin; D009124:Muscle Proteins; D020033:Protein Isoforms; D011494:Protein Kinases; D017868:Cyclic AMP-Dependent Protein Kinases; D007545:Isoproterenol
Circ Res. 2002 Jun 14;90(11):1181-8
12065321
J Physiol. 2002 Aug 1;542(Pt 3):911-20
12154188
Circulation. 2002 Sep 10;106(11):1333-41
12221049
Circulation. 2002 Sep 10;106(11):1384-9
12221057
J Physiol. 2002 Oct 1;544(Pt 1):171-82
12356890
J Physiol. 2002 Nov 1;544(Pt 3):817-30
12411526
Circ Res. 1995 Jun;76(6):1028-35
7758157
J Gen Physiol. 2003 Feb;121(2):97-110
12566538
J Physiol. 2003 Mar 15;547(Pt 3):951-61
12562915
J Muscle Res Cell Motil. 2002;23(5-6):473-82
12785098
Biophys J. 2003 Nov;85(5):3142-53
14581214
J Physiol. 2003 Nov 15;553(Pt 1):147-54
12963792
J Physiol. 2004 May 1;556(Pt 3):835-47
14966306
Circulation. 2004 Jul 13;110(2):155-62
15238456
Curr Vasc Pharmacol. 2004 Apr;2(2):135-9
15320514
Exp Physiol. 2004 Sep;89(5):573-82
15184354
Circ Res. 2004 Oct 1;95(7):708-16
15345656
Circ Res. 1978 Oct;43(4):553-61
210973
Circ Res. 1980 May;46(5):703-14
7363419
Am J Physiol. 1980 Jul;239(1):H101-7
7396007
J Biol Chem. 1982 Jan 10;257(1):260-3
7053370
Am J Physiol. 1982 Mar;242(3):H411-20
7065201
Biophys J. 1982 Nov;40(2):109-20
7171707
Circ Res. 1986 Jun;58(6):755-68
3719928
Pflugers Arch. 1987 Aug;409(4-5):427-37
2442710
Can J Physiol Pharmacol. 1987 Aug;65(8):1658-65
2825941
Circ Res. 1988 Feb;62(2):247-65
2827909
Circ Res. 1988 Mar;62(3):452-61
3342474
Biochem J. 1988 Feb 1;249(3):709-14
2895634
J Pharmacol Methods. 1988 May;19(3):267-74
3393008
Circ Res. 2000 Jan 7-21;86(1):59-67
10625306
Circ Res. 2000 Jan 7;86(1):E1-6
10625312
Am J Physiol Heart Circ Physiol. 2000 Mar;278(3):H769-79
10710345
Cardiovasc Res. 2000 May;46(2):316-23
10773236
Biochem Biophys Res Commun. 2000 May 27;272(1):104-10
10872811
J Mol Cell Cardiol. 2000 Dec;32(12):2151-62
11112991
Circ Res. 2001 May 25;88(10):1059-65
11375276
Biophys J. 2001 Oct;81(4):2297-313
11566799
Circ Res. 2001 Nov 9;89(10):874-81
11701614
Circ Res. 2001 Dec 7;89(12):1184-90
11739284
Nature. 2002 Jan 10;415(6868):198-205
11805843
J Physiol. 2002 Jun 1;541(Pt 2):335-42
12042342
Circulation. 1989 Feb;79(2):371-82
2536598
J Physiol. 1990 Apr;423:221-40
1696985
Circ Res. 1991 Feb;68(2):382-91
1825034
Circulation. 1991 Sep;84(3):1040-8
1653121
Am J Physiol. 1992 Jul;263(1 Pt 2):H293-306
1636767
J Physiol. 1993 Feb;461:167-84
8394423
Biochem J. 1993 Sep 1;294 ( Pt 2):401-6
8396912
Am J Physiol. 1994 Mar;266(3 Pt 2):H1007-18
8160804
Am J Physiol. 1994 Mar;266(3 Pt 2):H1138-44
8160816
J Am Coll Cardiol. 1995 Feb;25(2):295-304
7829780
Biophys J. 1995 Mar;68(3):1027-44
7756523
J Mol Cell Cardiol. 1995 Jul;27(7):1383-91
7473784
Circ Res. 1996 Sep;79(3):619-26
8781495
Am J Physiol. 1997 Sep;273(3 Pt 2):H1068-74
9321790
Curr Opin Cell Biol. 1999 Feb;11(1):18-25
10047523
J Physiol. 1999 May 15;517 ( Pt 1):143-57
10226156
Circ Res. 1999 Jun 11;84(11):1339-52
10364572
Pflugers Arch. 2005 Feb;449(5):449-57
15688246